Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Araújo Santos, Théo ^a,b   Andrade, Bruno B ^a,c,d,e,f   Gil Santana, Leonardo ^a,c,d   Luz, Nívea F ^a   Dos Santos, Priscila L ^g   De Oliveira, Fabrícia A ^g   Almeida, Meirielly Lima ^g   De Santana Campos, Roseane Nunes ^g   Bozza, Patrícia T ^a   Almeida, Roque P ^g,h   Borges, Valeria M ^a,i  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Programa de Pós graduação em História   (Brazil)

^c Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER)   (Brazil)

^d Curso de Medicina   (Brazil)

^e Universidade Salvador   (Brazil)

^f ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^g FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^h Instituto Nacional de Ciencia e Tecnologia de Investigacao em Imunologia III INCT   (Brazil)

ⁱ FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; AUTACOID; BIOLOGICAL MARKER; CYTOKINE;

ADOLESCENT; BLOOD; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEISHMANIA DONOVANI; MALE; METABOLISM; PARASITOLOGY; VISCERAL LEISHMANIASIS; YOUNG ADULT;

ADOLESCENT; ANTIPROTOZOAL AGENTS; BIOMARKERS; CHILD; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; YOUNG ADULT;

EID: 85021667047     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-04595-8     Document Type: Article

References (42)

1. Ministério da Saúde, Brasil. Visceral leishmaniasis: clinical recommendations for lethality reduction. 78p (2011).
2. Costa, D. L. et al. Serum cytokines associated with severity and complications of kala-azar. Pathog Glob Health 107, 78-87, doi:10.1 179/2047773213Y.0000000078 (2013).
3. Peruhype-Magalhaes, V. et al. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol 62, 487-495, doi:10.1111/j.1365-3083.2005.01686.x (2005).
4. Peruhype-Magalhaes, V. et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 146, 124-132, doi:10.1111/j.1365-2249.2006.03171.x (2006).
5. Holaday, B. J. et al. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest 92, 2626-2632, doi:10.1172/JCI116878 (1993).
6. Nylen, S. & Sacks, D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28, 378-384, doi:10.1016/j.it.2007.07.004 (2007).
7. Gollob, K. J., Viana, A. G. & Dutra, W. O. Immunoregulation in human American leishmaniasis: balancing pathology and protection. Parasite Immunol 36, 367-376, doi:10.1111/pim.12100 (2014).
8. Belo, V. S. et al. Risk factors for adverse prognosis and death in American visceral leishmaniasis: a meta-analysis. PLoS Negl Trop Dis 8, e2982, doi:10.1371/journal.pntd.0002982 (2014).
9. Bozza, P. T., Bakker-Abreu, I., Navarro-Xavier, R. A. & Bandeira-Melo, C. Lipid body function in eicosanoid synthesis: an update. Prostaglandins Leukot Essent Fatty Acids 85, 205-213, doi:10.1016/j.plefa.2011.04.020 (2011).
10. Dennis, E. A. & Norris, P. C. Eicosanoid storm in infection and inflammation. Nat Rev Immunol 15, 511-523, doi:10.1038/nri3859 (2015).
11. Franca-Costa, J. et al. Differential Expression of the Eicosanoid Pathway in Patients With Localized or Mucosal Cutaneous Leishmaniasis. J Infect Dis 213, 1143-1147, doi:10.1093/infdis/jiv548 (2016).
12. Malta-Santos, H. et al. Resolvin D1 drives establishment of Leishmania amazonensis infection. Sci Rep 7, 46363, doi:10.1038/srep46363 (2017).
13. Araujo-Santos, T. et al. Role of prostaglandin F2alpha production in lipid bodies from Leishmania infantum chagasi: insights on virulence. J Infect Dis 210, 1951-1961, doi:10.1093/infdis/jiu299 (2014).
14. Solca, M. S. et al. Circulating Biomarkers of Immune Activation, Oxidative Stress and Inflammation Characterize Severe Canine Visceral Leishmaniasis. Sci Rep 6, 32619, doi:10.1038/srep32619 (2016).
15. Franca-Costa, J. et al. Arginase I, polyamine, and prostaglandin E2 pathways suppress the inflammatory response and contribute to diffuse cutaneous leishmaniasis. J Infect Dis 211, 426-435, doi:10.1093/infdis/jiu455 (2015).
16. Ansari, N. A., Saluja, S. & Salotra, P. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clin Immunol 119, 339-345, doi:10.1016/j.clim.2006.01.017 (2006).
17. van der Poll, T., Zijlstra, E. E. & Mevissen, M. Interleukin 6 during active visceral leishmaniasis and after treatment. Clin Immunol Immunopathol 77, 111-114 (1995).
18. Dos Santos, P. L. et al. The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14. PLoS Negl Trop Dis 10, e0004375, doi:10.1371/journal.pntd.0004375 (2016).
19. Frade, A. F. et al. TGFB1 and IL8 gene polymorphisms and susceptibility to visceral leishmaniasis. Infect Genet Evol 11, 912-916, doi:10.1016/j.meegid.2011.02.014 (2011).
20. Karp, C. L. et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest 91, 1644-1648, doi:10.1172/JCI116372 (1993).
21. de Medeiros, I. M., Castelo, A. & Salomao, R. Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 40, 31-34 (1998).
22. Bacellar, O., D'Oliveira, A. Jr., Jeronimo, S. & Carvalho, E. M. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 12, 1228-1231, doi:10.1006/cyto.2000.0694 (2000).
23. Caldas, A. et al. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 5, 113, doi:10.1186/1471-2334-5-113 (2005).
24. Saha, S. et al. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 179, 5592-5603 (2007).
25. Luz, N. F. et al. Heme oxygenase-1 promotes the persistence of Leishmania chagasi infection. J Immunol 188, 4460-4467, doi:10.4049/jimmunol.1103072 (2012).
26. Gautam, S. et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis 204, 1134-1137, doi:10.1093/infdis/jir461 (2011).
27. Barral-Netto, M. et al. Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis 163, 853-857 (1991).
28. Medeiros, I. M., Reed, S., Castelo, A. & Salomao, R. Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis. Clin Microbiol Infect 6, 34-37 (2000).
29. Salomao, R., Castelo Filho, A., de Medeiros, I. M. & Sicolo, M. A. Plasma levels of tumor necrosis factor-alpha in patients with visceral leishmaniasis (Kala-azar). Association with activity of the disease and clinical remission following antimonial therapy. Rev Inst Med Trop Sao Paulo 38, 113-118 (1996).
30. Barral-Netto, M. et al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257, 545-548 (1992).
31. Rodrigues, V. Jr., Santana da Silva, J. & Campos-Neto, A. Transforming growth factor beta and immunosuppression in experimental visceral leishmaniasis. Infect Immun 66, 1233-1236 (1998).
32. Costa, A. S. et al. Cytokines and visceral leishmaniasis: a comparison of plasma cytokine profiles between the clinical forms of visceral leishmaniasis. Mem Inst Oswaldo Cruz 107, 735-739 (2012).
33. Bacellar, O., Barral-Netto, M., Badaro, R. & Carvalho, E. M. Gamma interferon production by lymphocytes from children infected with L. chagasi. Braz J Med Biol Res 24, 791-795 (1991).
34. Hailu, A., van der Poll, T., Berhe, N. & Kager, P. A. Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg 71, 561-567 (2004).
35. Kurkjian, K. M. et al. Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 69, 353-358, doi:10.1002/cyto.a.20256 (2006).
36. Lima-Junior, D. S. et al. Inflammasome-derived IL-1beta production induces nitric oxide-mediated resistance to Leishmania. Nat Med 19, 909-915, doi:10.1038/nm.3221 (2013).
37. Gazzinelli, R. T., Oswald, I. P., James, S. L. & Sher, A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gammaactivated macrophages. J Immunol 148, 1792-1796 (1992).
38. Bogdan, C., Vodovotz, Y. & Nathan, C. Macrophage deactivation by interleukin 10. J Exp Med 174, 1549-1555 (1991).
39. Oswald, I. P., Wynn, T. A., Sher, A. & James, S. L. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proc Natl Acad Sci U S A 89, 8676-8680 (1992).
40. Kumar, R. & Nylen, S. Immunobiology of visceral leishmaniasis. Front Immunol 3, 251, doi:10.3389/fimmu.2012.00251 (2012).
41. Andrade, B. B. et al. Heme impairs prostaglandin E2 and TGF-beta production by human mononuclear cells via Cu/Zn superoxide dismutase: insight into the pathogenesis of severe malaria. J Immunol 185, 1196-1204, doi:10.4049/jimmunol.0904179 (2010).
42. Gomes, N. A., Gattass, C. R., Barreto-De-Souza, V., Wilson, M. E. & DosReis, G. A. TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar. J Immunol 164, 2001-2008 (2000).